CHICAGO — An investigational remedy from Eli Lilly helped protect lean mass and drive higher lack of fats in sufferers taking the favored weight problems remedy Wegovy.
In a Part 2 trial, sufferers taking the highest-dose mixture of Wegovy and the drug, referred to as bimagrumab, misplaced 22% of their weight at 72 weeks. Ninety-three p.c of that was fats mass, and the remainder was lean mass. Folks taking Wegovy alone misplaced a smaller 16% of their weight, and 72% of that was fats mass, in keeping with outcomes that shall be introduced Monday on the American Diabetes Affiliation assembly.
Sufferers taking the mixture skilled an estimated 58% discount in visceral fats, the kind of fats within the stomach that’s considered significantly dangerous. That compares with a drop of 36% in these taking Wegovy alone.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
